Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.

@article{Graham2006EvaluationOT,
  title={Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.},
  author={Claire Graham and Chandra Tucker and Jeremy Creech and Edward G. Favours and Catherine A. Billups and Tiebin Liu and Maryam Fouladi and Burgess B Freeman and Clinton F Stewart and Peter James Houghton},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2006},
  volume={12 1},
  pages={223-34}
}
PURPOSE Histone acetyltransferases and histone deacetylases (HDAC) control the acetylation state of histones and other proteins regulating transcription and protein function. Several structurally diverse HDAC inhibitors have been developed as cancer therapeutic agents and in vitro have been shown to cause differentiation, cell cycle arrest, or apoptosis. Here, we have evaluated depsipeptide, a natural tetrapeptide HDAC inhibitor, against a panel of pediatric solid tumor models in vivo and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2016
View 1 Excerpt

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma

Acta neuropathologica communications • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…